Home » Illumina Gets Emergency Use Authorization for Sequencing-Based COVID-19 Test
Illumina Gets Emergency Use Authorization for Sequencing-Based COVID-19 Test
Illumina has obtained the FDA’s first Emergency Use Authorization (EUA) for a sequencing-based COVID-19 diagnostic.
The EUA covers the company’s COVIDSeq test, a high-throughput, sequencing-based in vitro diagnostic that detects SARS-CoV-2 by targeting the full viral genome.
The diagnostic tests upper respiratory specimens, including nasopharyngeal or oropharyngeal swabs, and delivers results in 24 hours using the company’s NovaSeq 6000 Sequencing System.
Upcoming Events
-
21Oct